di se ase t h erapy 1992, comprised six sess io n s l)vcr three Jays and attrac ted more t han 400 participants. The first session, "Progress in the pathoge n esis of !B[)", comprised e ig ht sess iom, including: "Cenetics and epide111iology", "Neunipeptides", "Cranuloma for111at illll", "Intestinal macrophages", "T cel l-induced 111ucosa l c h ange~". "Complement depositi o n ", "Autoimmuni t y", and ,rn overview, "Progress in pathogenesis."
The second session co ncerned "Path oge nesis and rharmace uti cs", in an a ttempt rn li nk presc rirrio n of drugs direc tly to inte rfere with path,,genic mec h a nism s. This sessiun comprised "l mmunosupp ress ive therapy" , " Inflammation mediator blockers", "Corticosterrnd t h erapy: O ld ;md n ew", and "Anti-infectio us t herapy".
The third session addressed "!RD epidemiol,1gy and diagn osis: O ngo ing issues and new ideas". This involved six speakers giving t h eir perspectives on "Epidemiology: Unanswered questio ns from Europe , and fr,)m C anada , IBD in a defi ned Nort h American popu lation", "A q uality of life 111dex for IBO", "!RD a nd NSA IDs", and ''Indeterminate coli tides".
The fi.lurth sess km on "Therapy of acute episodes of !RD was introduced by a deba te, "Arc placebo triab eth ical in IBD t herapy?" fo llowed hy fo ur topics; ''5-ASA th e r:1py in !RD:
W h at is new s ince 1990!" , "Gut tox icity o( 5-ASA", " Interleuki n, and IRD", and "f'rosrnglandins in lBD T h e rary".
The re were fo ur d iscussio ns in ulce rati ve co litis; "Lidncaine as topical tremment of di srn l ulcerati\'e coli tis", "Zilcuton: A placebo controlled t ri al in ac ute ulcerative coli tis", " lmmunoglo hu lin therapy in IBD", and "The use lit' cyc l,1spu rine in the treat ment o f severe act ive u lce rati ve col iti s". There were five contribut ion, for C rohn's disease; "Pediat ri c i,sues in IBl) 70 therary", "Srecial is:,ues in nutrit1lln therapy", "Defined formula diet:, in C rohn's disease", "Elemental ve rsus Jlolymetri c diet in Crnhn's d isease", and "FX506 in ac utl' C mhn', di scase". The fifth , ess ion concerned "Recurren ce a nd its preve ntion". There was an intmductmy ,cssion ,m "The problem ,,I rec urrence in Cmhn\ di sease" . There were four sess io n s on "Predicting rccmrence", as fi1llows: "Clinical pred1ct,)r, nf recurrence in I BO", "The pathl)logy of recurrence", " lmmunul<1gical predict,ll's llf recurrence", a nd " Predic ti ng recu rrence using , 1mple tests". The scc,md part cnnce rned "Managing re lapse, induc ing remb,ion", \\'ith fiv e contrihutions: "Prevent io n of relapse in ulcern ti,·e culiti s using o ra l or topi ca l 5-ASA rherapy" , "Preventing relapse in C rohn's di sease", "Cyclllsporine in Crnhn 's disease", "Comparati ve studv o i m a l 4 -ASA ver,us 5-ASA m the maintenance treatme nt of Crohn 's di,ease" a nd "The , tenHd -re,istant patient".
Fina lly, "Contnl\'ersie, in the surg ic.il management ,11'
IBO" was the topic lif se,sinn V I. There were six contrihurions, "Crohn's di sease: The henefits llf' extens ive surgery", cont rasted with "Crohn 's d isease: The hcncfit s of mi ni mal ~u rgery", "llclianal plluc h: Muco,cc t,Hny e,scn t ia l !", "I leoa nal po uc h es: Mucnsectomy unnecessary 1 ", "f'erianal Crohn's di sease: Cnnse rva t ive approach", and "Pcrianal Crnhn\ di sease: Active nppmach". There were t hi rty-nine paper, received a nd accepted for th is issue. 
